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Non-Hodgkin lymphoma comprises a disparate set of malignan-
cies of lymphoid tissue, other than Hodgkin’s disease, with a wide
variety of biological, clinical and prognostic features. The clinical
classification of lymphomas has changed considerably in response
to advances in medical knowledge, but it has been difficult to
assimilate these changes into the International Classification of
Diseases (ICD) for Oncology, used by population-based cancer
registries for coding cases for international comparison of cancer
incidence (Percy et al, 1984). The tenth revision of the ICD
provided more rubrics for non-Hodgkin lymphoma (C82–C85,
C91.4, C96) than the two available in ICD-9 (200, 202), but cancer
registry data were only coded to ICD-10 from 1995 or later.
As a result, it is not yet possible to provide long-term
comparisons of incidence and survival trends for specific types
of non-Hodgkin lymphoma with population-based data. This is
also true of mortality data, which were only coded to ICD-10 from
2000 or later, and which are derived from the limited diagnostic
information on death certificates, as opposed to the medical
records used to register newly diagnosed cases. Mortality data are
generally reported for all the non-Hodgkin lymphomas combined.
We present survival trends for the same broad category of all the
non-Hodgkin lymphomas combined.
Non-Hodgkin lymphoma is the most common lympho-haemo-
poietic malignancy in adults. It ranks as the eighth most common
malignancy with almost 8000 new cases diagnosed each year. The
male–female ratio is approximately 1.5. Non-Hodgkin lymphoma
has tripled in frequency in both sexes since the early 1970s (Quinn
et al, 2001), an increase echoed in many countries (Coleman et al,
1993). More than 60% of cases arise in persons aged 60 years or
more, and the increase in incidence has been up to five-fold in
older men and women, with little change in young adults.
Incidence is slightly higher in affluent than deprived men, but
there is no difference for women.
The causes of NHL are not well established, although solvents,
pesticides and other chemicals have been implicated (Blair and
Kazerouni, 1997; Lynge et al, 1997; Stellman, 1998). Certain viruses,
such as Epstein–Barr virus, HIV and HTLV are known to be
potentially lymphoma-inducing (IARC, 1996, 1998), whereas onco-
genic viruses have recently been suspected (Metayer et al, 1998).
We analysed the data for 78894 patients registered with non-
Hodgkin lymphoma as a first primary malignancy in England and
Wales during the period 1986–1999, some 86% of those eligible.
Nine per cent of cases were excluded from survival analysis
because their recorded survival was zero (date of diagnosis same as
date of death): most of these will have been registered from a death
certificate only (DCO); hence, their date of diagnosis and their
duration of survival were both unknown. These cases could not be
reliably distinguished from cases with true zero survival in the
national data. The proportion of cases excluded from analysis as
DCO was similar in all deprivation groups, and this is unlikely to
have had a material impact on estimates of trend or socioeconomic
gradient in survival. A further 3% of patients were excluded
because the lymphoma was not their first primary malignancy,
along with 1.8% whose vital status was unknown at 5 November
2002, when the data were extracted for analysis.
SURVIVAL TRENDS
One-year survival rose from 66 to 70% in both sexes: after
adjustment for differences among deprivation groups, that
represents an increase of approximately 2% every 5 years (Table 1,
Figure 1). Five-year survival rose more quickly than 1-year
survival, from 46% for patients diagnosed during 1986–1990 to
approximately 52% for those diagnosed during 1996–1999, a
deprivation-adjusted increase of approximately 4% every 5 years.
Both rates of increase are statistically significant. For patients
diagnosed during 1996–1999, the 5-year relative survival reached
51% for men and 53% for women.
Hybrid analysis of the survival probabilities observed during
2000–2001 (Brenner and Rachet, 2004) suggests that the recent
improvement in survival observed during the late 1990s is likely to
continue (Figure 1, dashed line). Survival rates predicted for those
diagnosed during 2000–2001 are approximately 70–71%, 53–54%
and 44–45% at 1, 5 and 10 years after diagnosis, respectively (Table 1).
DEPRIVATION
Survival at 1, 5 and 10 years after diagnosis is substantially and
systematically higher among more affluent groups. Among
more than 26000 patients diagnosed during 1996–1999, the
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and the most affluent groups were estimated at 5–7% (Table 2,
Figure 2).
After adjusting for temporal trends in survival, the fitted
deprivation gap is statistically significant in every case, with
the exception of 10-year survival for patients diagnosed during
1986–1990.
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 66.0 (65.1, 66.8) 66.9 (66.1, 67.6) 69.5 (68.7, 70.3) 2.2** (0.6, 3.8) 70.0 (68.9, 71.2)
Women 65.8 (64.9, 66.8) 67.5 (66.6, 68.3) 69.9 (69.0, 70.7) 2.4** (0.7, 4.1) 70.9 (69.7, 72.1)
5 year Men 45.8 (44.8, 46.9) 47.0 (46.1, 47.9) 51.3 (50.2, 52.4) 4.0** (2.0, 5.9) 52.6 (51.2, 54.0)
Women 46.2 (45.1, 47.2) 49.1 (48.1, 50.0) 52.7 (51.5, 53.9) 3.6** (1.4, 5.8) 53.9 (52.4, 55.3)
10 year Men 38.0 (36.9, 39.1) 39.4 (38.3, 40.5) 3.5 ( 0.4, 7.3) 44.7 (43.1, 46.2)
Women 36.2 (35.1, 37.3) 40.3 (39.1, 41.5) 8.7** (4.5, 12.9) 43.8 (42.1, 45.4)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival estimated with
cohort or complete approach (1986–1990, 1991–1995, 1996–1999) or hybrid
approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival
(%) by sex and calendar period of diagnosis: England and Wales,
adults (15–99 years) diagnosed during 1986–1999 and followed up
to 2001.
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slight widening (approximately  1% every 5 years) is not
statistically significant (Table 2). The exception here is 10-year
survival for women, where the deprivation gap has increased
significantly.
Short-term predictions with hybrid analysis suggest that the
socioeconomic differences in survival up to 10 years after
diagnosis are likely to remain wide for the foreseeable future
(Table 2).
COMMENT
Steadily improving survival for patients with non-Hodgkin lym-
phoma in England and Wales during the 1990s continues a trend
that has been evident for more than 20 years. Five-year survival for
patients diagnosed during the early 1970s was approximately 30%,
reaching 40–45% in the 1980s (Coleman et al, 1999) and now 52%
for patients diagnosed in the late 1990s. This steady trend probably
reflects progress in treatment, especially radiotherapy and che-
motherapy, since the early 1980s. Survival in England and Wales is
still lower than, although close to, figures reported from other
western European countries (Sant et al, 2003).
The improvement in overall survival has not led to greater
equity in outcome. Survival for the least affluent remains
substantially lower than for the most affluent, even after
adjustment for the differences and trends in background mortality
among deprivation categories; without that adjustment, the
observed difference in survival would be even greater.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  5.1** ( 7.6,  2.5)  7.7** ( 10.0,  5.5)  5.9** ( 8.3,  3.6)  0.4 ( 2.2, 1.4)  6.7** ( 9.9,  3.4)
Women  5.0** ( 7.7,  2.2)  8.0** ( 10.4,  5.6)  5.7** ( 8.1,  3.2)  0.3 ( 2.3, 1.6)  4.7** ( 8.1,  1.3)
5 years Men  4.4** ( 7.3,  1.5)  5.5** ( 8.1,  2.9)  7.3** ( 10.4,  4.1)  1.5 ( 3.8, 0.7)  7.5** ( 11.5,  3.6)
Women  5.3** ( 8.4,  2.2)  8.9** ( 11.6,  6.1)  5.4** ( 8.9,  1.9)  0.4 ( 2.8, 2.1)  3.5 ( 7.6, 0.7)
10 years Men  2.1 ( 5.2, 1.0)  4.9** ( 7.9,  1.8)  2.7 ( 7.1, 1.6)  7.0** ( 11.5,  2.5)
Women  2.7 ( 6.0, 0.5)  8.7** ( 12.2,  5.3)  6.0* ( 10.7,  1.3)  8.2** ( 12.9,  3.4)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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